## C.V.

#### **Personal Information**

Name: Mohammed Ibrahim Mohammed Aladul

Date and place of birth: 1984 Mosul

**Nationality: Iraqi** 

**Gender: Male** 

**Marital status: Married** 

Current address: Al Muhandiseen qr., Mosul

Mobile: 07700401605

E-mail: sci.affairs.pharm@uoninevah.edu.iq

**Current work address: College of Pharmacy, Ninevah University** 

Previous work Address: University of Mosul, College of Pharmacy;

Avicenna Hospital, Ministry of Health

### **Scientific Qualifications**

Degree	<b>Graduation Year</b>	<b>Donar University</b>	Speciality
PhD	2018	<b>Keele University</b>	Pharmacy
			Practice
Master	2013	Hawler Medical	Clinical
		University	Pharmacy
Bachelor	2007	<b>University of Mosul</b>	Pharmaceutical
			Sciences

## Work history and experience

Job	Organization	Period
Pharmacist	Avicenna Hospital	2007-2008
Pharmacist	College of Pharmacy	2008-2013
Assistant lecturer	College of Pharmacy	2014-2018
Lecturer	College of Pharmacy	2019-2020

## **Positions** and committees membership

	Position	From	То
1	<b>Procurement Committee</b>	2009	2010
2	<b>Clinical Pharmacy Department director</b>	2013	2014
3	Dean Deputy for Scientific Affairs	2020	-
4			

### **Publications**

Chapman SR, Fitzpatrick RW, Aladul MI. Has cost inhibited the uptake of more potent statins in England? Pharmacoepidemiology & Drug Safety 2017; doi:10.1002/pds.4231.

Chapman SR, Fitzpatrick RW, Aladul MI. What drives the prescribing of growth hormone preparations in England? Prices versus patient preferences. BMJ Open 2017;7:e013730. doi:10.1136/bmjopen-2016-013730.

Aladul MI, Fitzpatrick RW, Chapman SR. Impact of infliximab and etanercept biosimilars on biological disease modifying antirheumatic drugs utilisation and NHS budget in UK. BioDrugs. 2017. doi: 10.1007/s40259-017-0252-3.

Chapman SR, Fitzpatrick RW, Aladul MI. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of

a UK web-based survey. BMJ Open 2017;0:e016730. doi:10.1136/bmjopen-2017-016730.

Aladul MI, Fitzpatrick RW, Chapman SR. Patients' understanding and attitudes towards infliximab and etanercept biosimilars: Result of a UK web-based survey. BioDrugs. 2017;31(5), 439-446. doi: 10.1007/s40259-017-0238-1.

Aladul MI, Fitzpatrick RW, Chapman SR. Differences in UK healthcare professionals' knowledge, attitude and practice towards infliximab and insulin glargine biosimilars. International Journal of Pharmacy Practice. 2018. doi:10.1111/ijpp.12485.

Aladul MI, Fitzpatrick RW, Chapman SR. Healthcare professionals' perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study. BMJ Open 2018;0:e023603. doi:10.1136/bmjopen-2018-023603.

Aladul MI, Fitzpatrick RW, Chapman SR. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis. Research in social and administrative pharmacy. 2018. doi: 0.1016/j.sapharm.2018.05.009.

Chapman SR, Aladul MI, Fitzpatrick RW. Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysisBMJ Open 2019;9:e026817. doi: 10.1136/bmjopen-2018-026817

Chapman SR, Fitzpatrick RW, Aladul MI. Did cost inhibit the uptake of more potent statins? Pharmacoepidemiology & Drug Safety 2016; 25, 7. doi: 10.1002/pds.4019.

Aladul M, Fitzpatrick R, Chapman S. Is the uptake in use of biosimilars similar to generic medicines? Prescribing and Research in Medicines Management (UK & Ireland) Annual Conference 2017, University of Coventry London Campus, January 28th, 2017: "Deprescribing - is less more?". Pharmacoepidemiol Drug Saf, 26: 3–20. doi:10.1002/pds.4221.

Aladul M, Fitzpatrick R, Chapman S. CP-024 Factors affecting uptake of biosimilars Eur J Hosp Pharm 2017;24:A10-A11. doi:10.1136/ejhpharm-2017-000640.23.

Aladul M, Fitzpatrick R, Chapman S. 4CPS-131 Differences in UK healthcare professionals' knowledge, attitude and practice towards infliximab and insulin glargine biosimilars. Eur J Hosp Pharm 2018;25(suppl 1):A103. doi:10.1136/ejhpharm-2018-eahpconf.222.

Aladul M, Fitzpatrick R, Chapman S. Impact of subcutaneous trastuzumab on the uptake of intravenous trastuzumab in UK. Madridge J Pharm Res 2018, 3:2. doi:10.18689/MJPR.2018.A1.003.

Aladul M, Fitzpatrick R, Chapman S. Differences in uptake of rituximab biosimilars among UK medical specialities. BMJ 2018.

Aladul M, Al-Qazaz H Kh. Allela OQB. Healthcare professionals' knowledge, perception and practice towards COVID-19: A cross-sectional web-survey Journal of Pharmaceutical Health Services Research 11 (4), 355-363

# **Conference presentation**

Conference tit	le	Date
Prescribing and	d Research in Medicines	2016
Management (	UK & Ireland) Annual Conferen	ce
2016- London		
Prescribing and	d Research in Medicines	2017
Management (	UK & Ireland) Annual Conferen	ce
2017-Coventry	/	
European Asso	ociation of Hospital Pharmacists	- 2017
Cannes-France		
European Asso	ociation of Hospital Pharmacists	- 2018
Guttenberg – S	Sweden	
International P	harma Conference and Expo –	2018
Rome -Italy		
International F	Forum on Quality and Safety in	2018
Healthcare, Ar	nsterdam 2018	
Healthcare pro	fessionals' perceptions and	2019
perspectives or	n biosimilar medicines and the	
barriers and fac	cilitators to their prescribing -	
leiden Univers	ity- Netherlands.	

## **Teaching Experience**

U	Undergraduate			
	Topic	Academic Stage	Reference Text	
	Therapeutics	Fifth		
	TDM	Fifth		
	Pharmacoeconomics	Fifth		
	Principles of	First		
	<b>Pharmacy Practice</b>			
	Pharmaceutical			
	Calculations			